resmetirom
Sponsor Madrigal Pharmaceuticals, INC. · listed as MDGL
resmetirom is a drug asset sponsored by Madrigal Pharmaceuticals, INC., listed as MDGL. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Mar 2027 (month precision, medium confidence), tied to trial NCT04951219. That trial is in Phase 3 and currently active not recruiting, studying Non-Alcoholic Fatty Liver Disease. It appears across 3 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for resmetirom in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05500222 | Phase 3 | Active, not recruiting | 2026-12 | Active comparator | Madrigal Pharmaceuticals, Inc. | NASH; Cirrhosis, Liver |
| NCT04951219 catalyst | Phase 3 | Active, not recruiting | 2027-03 | Experimental | Madrigal Pharmaceuticals, Inc. | Non-Alcoholic Fatty Liver Disease |
| NCT03900429 | Phase 3 | Active, not recruiting | 2028-01 | Active comparator | Madrigal Pharmaceuticals, Inc. | NASH - Nonalcoholic Steatohepatitis |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More MDGL catalysts